Dr. Lal Path Labs Ltd.

rs 31

mpany 70+ years of experience in the field of diagnostics 100 Mn patients serviced in last 5 years 31 NABL accredited Labs; 2 CAP accredited Labs Largest* diagnostics chain in the country with PAN

20%

asis of revenue and presence Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl.

120%

s Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically sp

44%

ember 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 436 crore (Net

Rs. 436 crore

for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 436 crore (Net) Cash & Investments as on 30th June, 22 4,731 Patient Service Centres (PSC’s) 5,113 Patho

25%

P’s of Suburban Diagnostics As on March 31, 2022 Classification: Restricted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15%

INR 482

f Suburban Diagnostics As on March 31, 2022 Classification: Restricted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non

91%

arch 31, 2022 Classification: Restricted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non-Covid Patients 25% 18 M

INR 21

31, 2022 Classification: Restricted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non-Covid Patients 25% 18 Mn Non-Co

17%

Restricted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non-Covid Patients 25% 18 Mn Non-Covid Samples Margin 25

INR 503

icted 5 Q1 FY23 Snapshot 25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non-Covid Patients 25% 18 Mn Non-Covid Samples Margin 25% INR 126

15%

25% INR 482 Cr Non-Covid Revenue 91% INR 21 Cr Covid Revenue 17% INR 503 Cr Total Revenue 15% 7 Mn Non-Covid Patients 25% 18 Mn Non-Covid Samples Margin 25% INR 126 Cr Normalised EBITDA

Managing Director said

1

Chief Executive Officer said

1

Chief Executive Officer said

the on “The industry has more than adequate headroom to grow in FY23, where with an effective vaccination drive and improved patient has successfully met the challenges posed during the pandemic.. infrastructure, India care Dr Lal PathLabs is committed to control the epidemic of non-communicable diseases or lifestyle diseases that are responsible for nearly 65% deaths in India. Our methodical network capacity creation nationally, investments in technology, SwasthFit and focus on better service, will prepare us comprehensively to lead this space for time to come. Lal As a forward-thinking company, Dr. PathLabs has been at the forefront of incorporating technology into its business strategy.” “In the long run the market share transfer from the unorganized to the organized sector will accelerate due to a change in industry patterns. Customers appreciate the certainty of quality and effectiveness that a branded, national player provides, which unorganized players are unable to provide. We